Prognostic risk factors in advanced Hodgkin's lymphoma
Annals of Hematology1988Vol. 56(6), pp. 273–281
Citations Over TimeTop 10% of 1988 papers
Markus Loeffler, Michael Pfreundschuh, Dirk Hasenclever, Erhard Hiller, H Gerhartz, W. Wilmanns, R Rohloff, U. R�hl, G. K�hn, Roland J. Fuchs, Hartmut Kirchner, J. V. Teichmann, W. D. Schoppe, S. Petsch, W. Wilhelmy, P. Worst, K. -H. Pfl�ger, Th. Hecht, H. Bartels, W. Gaßmann, G. Kr�ger, G. Schmitz, W. H. Oertel, Volker Diehl
Related Papers
- → Chemotherapy of Hodgkin’s lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group(1989)20 cited
- → Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy(1999)5 cited
- → Therapiestudien der deutschen Hodgkin-Studiengruppe(1987)7 cited
- → Therapie der Hodgkin-Lymphome(1988)13 cited
- [Comparative study of advanced-stage Hodgkin's lymphoma patients treated with either COPP or ABVD drug combinations].(1992)